Riccardo Danielli

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott, Mahrukh Huseni, Michael B. Atkins et al. · Nature Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

Elisabetta Fratta, Sandra Coral, Alessia Covre et al. · Molecular Oncology · 2011 · 379 citations · Full text

Medicine, Immunology, Oncology +16

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Oncology · 2013 · 354 citations

Medicine, Oncology, Pharmacology +11

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Anna Maria Di Giacomo, Riccardo Danielli, Massimo Guidoboni et al. · Cancer Immunology Immunotherapy · 2009 · 280 citations · Full text

Life Sciences, Immunology, Oncology +17

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Luana Calabrò, Aldo Morra, Diana Giannarelli et al. · The Lancet Respiratory Medicine · 2018 · 216 citations

Pharmacy, Oncology, Pharmacotherapy +9